A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
← catalyst calendarNCT05519475 · readout in 617 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
120estimated
Sites
71
Countries
Japan, Puerto Rico, South Korea +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-02-09 | actual | When the study began enrolling |
| Primary completion | 2028-04-27 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-07 | estimated | The whole study's end, after follow-up |
| First posted | 2022-08-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
Interventions
- Drug: ALN-HSD
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange in quantitative liver Fibrosis (qFibrosis)
measured Baseline to week 52
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed